StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) shareholders

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
30M of 30M shares
Institutional holders
422
94 new, 36 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 142 sales
Net sold $105.27M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (14.94%)
4,292,88114.94%13G (passive) amendmentNov 12, 2024
BlackRock, Inc.3,427,64511.60%13G (passive) amendmentSep 30, 2026
Krish S. Krishnan
Joint filing with Suma M. Krishnan (11.50%)
3,388,28311.50%13G (passive) amendmentMar 31, 2026
Avoro Capital Advisors LLC
Joint filing with Behzad Aghazadeh (9.10%)
2,565,5559.10%13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of KRYSValueChange% of portfolio
FMR LLC4,418,19714.93%$1.64B+44,2100.07%
BlackRock, Inc.4,181,43214.13%$1.55B+240,9760.02%
Avoro Capital Advisors LLC2,888,8889.76%$1.07B–9.64%
Vanguard Portfolio Management LLC1,574,9055.32%$585.34M+118,1780.03%
State Street Corp1,351,1584.56%$502.20M+36,7240.01%
Vanguard Capital Management LLC1,240,5674.19%$461.08M+75,2430.01%
Soleus Capital Management, L.P.939,2543.17%$349.09M−213,83312.03%
Capital World Investors777,8432.63%$289.10M−46,8770.03%
Vestor Capital, LLC700,9142.37%$78.19M+700,7144.88%
Geode Capital Management, LLC698,9932.36%$259.84M+55,0180.01%
Price T Rowe Associates Inc /Md/687,4002.32%$255.49M+202,3260.03%
Hood River Capital Management LLC663,3752.24%$246.56M+43,7891.79%
Redmile Group, LLC632,0052.14%$234.90M−41,50015.77%
William Blair Investment Management, LLC570,1531.93%$211.91M+162,9750.64%
Frazier Life Sciences Management, L.P.481,3071.63%$178.89M–3.90%
Dimensional Fund Advisors LP476,0381.61%$176.94M+7,0480.03%
First Trust Advisors LP324,9001.10%$120.76M−25,6210.07%
Invesco Ltd.324,7551.10%$120.70M+73,3820.01%
Goldman Sachs Group Inc298,8411.01%$111.07M+83,8920.01%
Northern Trust Corp283,7840.96%$105.47M+31,3210.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202642230M100.0%94 / 176109 / 363M1M
Q1 202636828M95.9%76 / 138105 / 364M2M
Q4 202533428M96.2%82 / 112104 / 272M2M
Q3 202528428M95.1%46 / 10786 / 322M2M
Q2 202527528M93.4%42 / 10197 / 633M3M
Q1 202529928M93.5%64 / 89112 / 272M2M
Q4 202426428M93.8%37 / 9498 / 521M2M
Q3 202428328M96.0%55 / 10689 / 156M2M
Q2 202424529M98.3%52 / 9972 / 405M2M
Q1 202423426M89.0%66 / 6382 / 254M3M
Q4 202319426M86.4%29 / 7365 / 204M3M
Q3 202318824M82.7%21 / 8952 / 143M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

385 funds held KRYS in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of KRYSValue% of fundAs of
Select Biotechnology Portfolio1,802,6226.09%$557.06M10.58%May 31, 2026
iShares Core S&P Small-Cap ETF1,580,3275.34%$587.36M0.53%Jun 30, 2026
Vanguard Total Stock Market Index Fund889,5483.01%$330.62M0.01%Jun 30, 2026
Fidelity Growth Company Fund788,5252.66%$243.68M0.25%May 31, 2026
SMALLCAP World Fund Inc752,2442.54%$279.59M0.30%Jun 30, 2026
iShares Russell 2000 ETF670,8702.27%$249.34M0.30%Jun 30, 2026
Vanguard Small-Cap Index Fund642,4902.17%$238.79M0.13%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund370,5031.25%$137.70M0.29%Jun 30, 2026
Hood River Small-Cap Growth Fund329,7801.11%$122.57M1.84%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF318,7411.08%$118.47M1.10%Jun 30, 2026
Vanguard Extended Market Index Fund301,1791.02%$111.94M0.11%Jun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund293,0360.99%$108.91M3.87%Jun 30, 2026
Fidelity Small Cap Index Fund285,6310.97%$97.43M0.29%Jul 31, 2026
iShares Russell 2000 Growth ETF241,2790.82%$89.68M0.58%Jun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF240,7600.81%$89.48M0.53%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Krish S. KrishnanPresident and CEO, Director, 10% owner1,567,8635.30%Sep 4, 2026
Suma KrishnanPresident, R&D, Director, 10% owner1,512,3625.11%Sep 4, 2026
John Charles ThomasEVP, General Counsel1,0000.00%Jun 26, 2026
Laurent Louis Jean GouxEVP, Head of International9190.00%Mar 6, 2026
Kathryn RomanoChief Accounting Officer22,3660.08%Mar 3, 2026
Dino A. RossiDirector46,5000.16%Nov 13, 2026
Daniel JanneyDirector76,4090.26%Sep 16, 2026
Catherine MazzaccoDirector––Sep 16, 2026
Julian S. GangolliDirector20,0000.07%Sep 16, 2026
Christopher MasonDirector––Sep 16, 2026
Everett Rand SutherlandDirector––Sep 16, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Dino A. Rossi
Director
Nov 12, 2026Gift−3,500––46,500
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,267$356.37$1.16M1,321,352
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−399$366.56$146.26K1,302,145
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−826$365.41$301.83K1,302,544
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−1,329$364.48$484.39K1,303,370
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−520$354.54$184.36K1,326,625
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−2,006$355.57$713.27K1,324,619
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−565$363.34$205.29K1,304,699
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,962$357.57$1.42M1,317,390
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,180$358.42$1.14M1,314,210
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,392$359.39$1.22M1,310,818
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−2,320$360.47$836.29K1,308,498
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−1,242$361.61$449.12K1,307,256
Suma Krishnan
President, R&D, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−1,992$362.65$722.40K1,305,264
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−573$363.34$208.19K1,350,153
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−2,010$362.65$728.93K1,350,726
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−1,214$361.61$438.99K1,352,736
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−2,266$360.46$816.80K1,353,950
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,357$359.39$1.21M1,356,216
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,143$358.42$1.13M1,359,573
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,981$357.57$1.42M1,362,716
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−3,297$356.37$1.17M1,366,697
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−2,029$355.57$721.45K1,369,994
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−520$354.54$184.36K1,372,023
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−405$366.56$148.46K1,347,543
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−847$365.42$309.51K1,347,948
Krish S. Krishnan
President and CEO, Director, 10% owner
Sep 4, 2026Sale(10b5-1 plan)−1,358$364.48$494.96K1,348,795
Dino A. Rossi
Director
Aug 14, 2026Gift−3,691––75,000
Dino A. Rossi
Director
Aug 14, 2026Sale−341$325.60$111.03K74,659
Dino A. Rossi
Director
Aug 14, 2026Sale−2,287$326.60$746.93K72,372
Dino A. Rossi
Director
Aug 14, 2026Sale−5,226$327.39$1.71M67,146
Dino A. Rossi
Director
Aug 14, 2026Sale−1,687$328.52$554.21K65,459
Dino A. Rossi
Director
Aug 14, 2026Sale−7,428$329.60$2.45M58,031
Dino A. Rossi
Director
Aug 14, 2026Sale−4,896$330.36$1.62M53,135
Dino A. Rossi
Director
Aug 14, 2026Sale−3,095$331.43$1.03M50,040
Dino A. Rossi
Director
Aug 14, 2026Sale−40$333.23$13.33K50,000
John Charles Thomas
EVP, General Counsel
Jun 25, 2026Option exercise+1,000$179.25$179.25K1,000
John Charles Thomas
EVP, General Counsel
Jun 25, 2026Sale(10b5-1 plan)−1,000$347.27$347.27K0
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−1,348$307.09$413.96K1,399,767
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−2,039$310.94$634.01K1,378,395
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−2,801$309.95$868.17K1,380,434
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−3,803$308.89$1.17M1,383,235
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−12,729$307.81$3.92M1,387,038
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−240$311.65$74.80K1,378,155
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−480$305.87$146.82K1,401,115
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−400$304.89$121.96K1,401,595
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−247$303.17$74.88K1,401,995
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−593$302.25$179.23K1,402,242
Suma Krishnan
President, R&D, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−320$300.75$96.24K1,402,835
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−11,461$307.68$3.53M1,461,523
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−589$306.33$180.43K1,472,984
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−544$304.81$165.82K1,473,573
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−4,830$308.47$1.49M1,456,693
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−2,784$309.49$861.62K1,453,909
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−2,652$310.43$823.26K1,451,257
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−964$311.36$300.15K1,450,293
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−40$312.23$12.49K1,450,253
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−176$303.17$53.36K1,474,117
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−640$302.24$193.43K1,474,293
Krish S. Krishnan
President and CEO, Director, 10% owner
Jun 4, 2026Sale(10b5-1 plan)−320$300.75$96.24K1,474,933

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.41%
3M shares short
Days to cover
12.2
At 0M shares a day
Change since last report
+3.7%
From 3M shares
Short volume, 20 days
75.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Krystal Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,408 shares on Sep 9, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Suma Krishnan
Director, Officer, 10% Stockholder
Sep 4, 202625,000$9.29MSep 4, 2026Founders Shares
Krish S. Krishnan
Director, Officer, 10% Stockholder
Sep 4, 202625,000$9.29MSep 4, 2026Founders Shares
Dino A. Rossi
Director
Aug 14, 202625,000$8.31MAug 14, 2026Acquired from public market
John Charles Thomas
Officer
Jun 25, 20261,000$347.27KJun 25, 2026Stock Option Exercise
Krish S. Krishnan
Director, Officer, 10% Stockholder
Jun 4, 202625,000$7.55MJun 4, 2026Founders Shares
Suma Krishnan
Director, Officer, 10% Stockholder
Jun 4, 202625,000$7.55MJun 4, 2026Founders Shares
John Charles Thomas
Officer
May 26, 2026642$193.90KMay 26, 2026Restricted Stock Vesting
Suma Krishnan
Director, Officer, 10% Stockholder
Mar 4, 202625,000$6.60MMar 4, 2026Founders Shares
Krish S. Krishnan
Director, Officer, 10% Stockholder
Mar 4, 202625,000$6.60MMar 4, 2026Founders Shares
Kathryn Romano
Officer
Mar 2, 2026750$200.70KMar 2, 2026Restricted Stock Vesting
Daniel Janney
Director
Feb 27, 202611,803$3.25MFeb 27, 2026Private Placement
Daniel Janney
Director
Feb 26, 20267,741$2.13MFeb 26, 2026Private Placement
Daniel Janney
Director
Feb 25, 2026700$192.50KFeb 25, 2026Private Placement
Daniel Janney
Director
Feb 24, 202613,825$3.71MFeb 24, 2026Private Placement
Daniel Janney
Director
Feb 24, 202637,895$10.11MFeb 24, 2026Option Granted 11/10/2016

Congress trades

1 trade in Krystal Biotech reported by 1 member of the House

MemberTypeTradedAmountFiled
Christopher L. Jacobs
NY27
BoughtDec 12, 2022$1K–15KJan 20, 2023

See a number that looks wrong?